Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Acalabrutinib 联合 Danvatirsen (AZD9150) 治疗复发/难治性弥漫大 B 细胞淋巴瘤的 I 期研究，包括循环肿瘤 DNA 生物标志物评估
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-22-2483
Mark Roschewski, Manish R Patel, Patrick M Reagan, Nakhle S Saba, Graham P Collins, Hendrik-Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen Burke, Rafael D White, Maria Udriste, Shringi Sharma, Brian Dougherty, Daniel Stetson, David Jenkins, Andrew Mortlock, Alessandra Forcina, Ve
肿瘤
淋巴瘤
B细胞
FlowCytometry
Human
Ki-67
